James Flaherty, MD
Interventional Cardiology · Chicago, ILNPI 1598793903
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,413 of the $37,946 with a category attached, or 61.7%. Edwards Lifesciences accounts for 80.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $17,882 and has fallen 73.4% since, to $4,765 in 2025.
Across 159 payments — averaging $238.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$30K
- Abbott$3K
- Boston Scientific$1K
- Abiomed$338
- Ancora Heart, Inc.$337
- W. L. Gore & Associates, Inc.$265
- plus $2K from 17 others
Across 24 payments — averaging $3127.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$46K
- Abbott$29K
What the payments were for
- Consulting fees$23,41362%
- Travel & lodging$5,03113%
- Food & beverage$9,50325%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 65 | $30,398 |
| Abbott | 37 | $3,439 |
| Boston Scientific | 19 | $1,296 |
| Abiomed | 5 | $338 |
| Ancora Heart, Inc. | 2 | $337 |
| W. L. Gore & Associates, Inc. | 4 | $265 |
| Medtronic | 3 | $246 |
| Shockwave Medical, Inc | 2 | $220 |
| Cardiovascular Systems Inc. | 2 | $179 |
| Cardiva Medical, Inc. | 4 | $178 |
| Recor Medical Inc | 1 | $172 |
| Philips North America LLC | 2 | $157 |
| ZOLL Circulation Inc | 1 | $154 |
| Biosense Webster, Inc. | 1 | $140 |
| Penumbra, Inc. | 1 | $115 |
| Biotronik Inc. | 1 | $85 |
| Pfizer | 1 | $73 |
| Stryker | 2 | $47 |
| Cordis US CORP. | 2 | $31 |
| Inari Medical, Inc. | 1 | $22 |
| Novo Nordisk | 1 | $22 |
| Chiesi USA, Inc. | 1 | $19 |
| Terumo Medical Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Edwards SAPIEN 3 Transcatheter Heart Valve$22,379
- MitraClip$1,522
- SAPIEN 3 Ultra RESILIA$598
- STINGRAY$356
- PASCAL$337
- AccuCinch$317
- GENERAL - THERAPIES$265
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$253
- Mitra Clip system$247
- Vascular Lithotripsy$195
- CARDIOFORM Septal Occluder$193
- MitraClip System$187
- Paradise Ultrasound Renal Denervation System$172
- COREVALVE EVOLUT R$170
- Xience Sierra Coronary Stent System$161
- NAVITOR$158
- TherOx DS2 Console$154
- Catheter$154
- Downstream Cartridge$154
- Coronary Orbital Atherectomy System$151
How this compares
$37,946 in reported general payments places this provider in the 85th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 44 | $67,457 |
| JardianceEmpagliflozin | 27 | $32,396 |
| EntrestoSacubitril/Valsartan | 22 | $31,996 |
| Repatha SureclickEvolocumab | 19 | $17,730 |
| Metoprolol Succinate | 162 | $2,746 |
| ClopidogrelClopidogrel Bisulfate | 178 | $2,691 |
| Atorvastatin Calcium | 165 | $2,483 |
| Rosuvastatin Calcium | 114 | $1,807 |
| Ezetimibe | 36 | $1,353 |
| Losartan Potassium | 89 | $1,073 |
| Amlodipine Besylate | 129 | $1,022 |
| Lisinopril | 80 | $900 |
| Carvedilol | 59 | $690 |
| Furosemide | 55 | $483 |
| Pravastatin Sodium | 22 | $441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $73 | $67,45744 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Chicago
- Atman ShahChicago$788K
- David StewartChicago$169K
- Hussam SuradiChicago$97K
- Anita AsgarChicago$85K
- Daniel SchimmelChicago$79K
- Ranya SweisChicago$62K
- Charles DavidsonChicago$62K
- Fareed Moses ColladoChicago$42K
- Ashvarya ManglaChicago$36K
- Marysa LeyaChicago$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.